Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Rhea-AI Summary
Lexeo Therapeutics (NASDAQ: LXEO) reported Q4 and full-year 2025 results and provided program updates on its cardiac genetic-medicine pipeline.
Key developments include FDA analytical comparability approval for LX2006 manufacturing, submission of the SUNRISE-FA 2 protocol/SAP, positive Phase I/II interim data for LX2006 and LX2020, a research collaboration with Johnson & Johnson, a $154 million October 2025 equity financing, and $246.6 million in cash expected to fund operations into 2028.
Positive
- FDA comparability approval for LX2006 manufacturing (HEK293 to Sf9), enabling planned pivotal use of Sf9 process
- Protocol and SAP for SUNRISE-FA 2 submitted to FDA, with FDA feedback expected in Q2 2026
- Positive LX2006 interim data showing statistically significant mFARS improvement and no Grade 3+ SAEs to date
- LX2020 biopsy data showing dose-dependent PKP2 expression and reduced arrhythmia burden in high-dose cohorts
- $154M equity financing closed October 2025 to advance registrational readiness
- $246.6M cash providing runway into 2028
Negative
- Research & Development expenses declined 13.9% YoY to $63.8M in 2025, potentially signaling lower near-term development spend
- General & Administrative expenses increased 43.6% YoY to $45.5M in 2025, pressuring operating leverage
- Net loss of $100.0M for 2025 reflects continued significant cash burn
Key Figures
Market Reality Check
Peers on Argus
LXEO fell 3.36% with peers also negative (e.g., OMER -5%, ALEC -4.31%, CAPR -2.43%, MREO -2.05%). Scanner data does not flag this as a sector-wide move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 05 | Q3 2025 earnings | Positive | -1.8% | Q3 results plus LX2006 FDA pooling path and Sf9 process endorsement. |
| Aug 14 | Q2 2025 earnings | Positive | +1.5% | Q2 results, LX2006 Breakthrough Therapy and $80M equity financing. |
| May 12 | Q1 2025 earnings | Positive | -2.2% | Q1 results with strong LX2006 and LX2020 interim efficacy signals. |
| Mar 24 | FY 2024 results | Positive | +50.9% | FY 2024 results plus LX2006 pivotal alignment and LX2020 early data. |
| Nov 13 | Q3 2024 earnings | Positive | -0.7% | Q3 2024 results, LX2006 RMAT and registrational endpoint alignment. |
Earnings releases often paired positive clinical or regulatory updates with mixed price reactions, including several selloffs on seemingly favorable news.
Over the past five earnings cycles from Nov 2024 through Nov 2025, Lexeo repeatedly combined financial updates with key LX2006 and LX2020 milestones. Prior quarters featured RMAT and Breakthrough Therapy designations, FDA alignment on pivotal design and manufacturing, strong LVMI and mFARS improvements, and multiple equity financings that extended runway into 2027–2028. Price reactions ranged from a 50.92% spike after FY 2024 results to modest declines on later 2025 updates, showing that strong clinical progress has not always translated into sustained post-earnings strength.
Historical Comparison
In the past five earnings events, LXEO’s average move was 9.54%. Today’s -3.36% post-earnings decline sits within that historical range and reflects a more muted, modestly negative response versus prior swings.
Across these earnings updates, Lexeo advanced LX2006 from early pivotal alignment and RMAT status toward a registrational path and commercial process readiness, while LX2020 progressed through HEROIC-PKP2 dose escalation with rising PKP2 expression and arrhythmia improvements.
Regulatory & Risk Context
An effective shelf on Form S-3 dated Nov 5, 2025 covers resale of up to 1,250,015 shares underlying pre-funded warrants held by a single stockholder. Lexeo is not selling shares under this registration and would only receive nominal cash equal to the $0.0001 per-share exercise price if exercised for cash.
Market Pulse Summary
This announcement combined Q4 and full-year 2025 results with clear operational momentum. LX2006 advanced toward a pivotal SUNRISE-FA 2 trial and eventual BLA, while LX2020 showed dose-related PKP2 expression and symptom improvement. Financially, Lexeo ended 2025 with $246.6M in cash and investments and a full-year net loss of $100.0M. Investors may watch upcoming FDA feedback on SUNRISE-FA 2, the planned 12‑month HEROIC PKP2 update, and ongoing expense trends across R&D and G&A.
Key Terms
type b meeting regulatory
statistical analysis plan (sap) technical
chemistry, manufacturing and controls (cmc) regulatory
biologic license application (bla) regulatory
process performance qualification (ppq) technical
phase i/ii medical
aav gene therapy medical
AI-generated analysis. Not financial advice.
SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following Type B meeting; study initiation on track for 1H 2026
First CMC Development and Readiness Program (CDRP) meeting for LX2006 in Q1 2026; aligned with FDA on flexible approach to process validation such as reduced PPQ manufacturing batches
Late-breaking oral presentations at the American College of Cardiology (ACC) Annual Meeting demonstrate continued, encouraging efficacy and safety data across LX2006 and LX2020 programs
Established research collaboration with Johnson & Johnson to explore targeted cardiac delivery of AAV gene therapy using novel, localized routes of administration
Strengthened leadership team with addition of new Chief Medical Officer and senior appointments bolstering cardiac expertise
Cash, cash equivalents and investments of
NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today provided business updates across its portfolio and reported financial results for the fourth quarter and full year 2025.
“Over the past year we have made meaningful progress across our cardiac pipeline, including significant advancements for both LX2006 and LX2020,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. “Most recently, we were pleased to be selected for two Late-Breaker presentations at the American College of Cardiology and appreciate the opportunity to engage the cardiology community around the future of precision medicine in cardiovascular care. Looking ahead, we remain focused on disciplined execution as we continue to advance our pipeline toward key milestones. With additional resources from our October financing, the expansion of our cardiac leadership team, and multiple announced preclinical research collaborations, we believe Lexeo is well positioned to drive significant long-term value for patients and shareholders.”
Program Updates and Recent Progress
LX2006 in Friedreich Ataxia (FA)
- In October 2025, Lexeo announced progress in FDA discussions and reported positive interim clinical data from both ongoing Phase I/II studies of LX2006 demonstrating an encouraging safety profile and evidence of meaningful cardiac and functional benefit. LX2006 was generally well tolerated and associated with improvements in cardiac structure, biomarkers, and functional outcomes, including reduced left ventricular mass index (LVMI) and improved modified Friedreich Ataxia Rating Scale (mFARS) scores across participants with more than six months of follow‑up.
- In November 2025, FDA approved the analytical comparability report establishing comparability between LX2006 HEK293 and Sf9 manufacturing processes, endorsing use of the optimized, Sf9 final commercial manufacturing process for LX2006 in the planned pivotal study and clearing comparability requirements to begin dosing patients.
- In February 2026, Lexeo submitted the final registrational trial design and statistical analysis plan (SAP) for the SUNRISE‑FA 2 pivotal study to the FDA following a Type B meeting. The proposed open-label study is generally consistent with previously communicated guidance on key design elements, such as study size, duration, patient population, and the LVMI primary endpoint, and incorporates FDA feedback on minimizing bias, including physician selection bias of study participants. Lexeo expects to receive final feedback from the FDA in the second quarter of 2026 and plans to provide a more detailed update at that time.
- In March 2026, Lexeo conducted an initial Chemistry, Manufacturing and Controls (CMC) Development and Readiness Program (CDRP) meeting with the FDA for LX2006, during which the agency reiterated its support for a flexible validation approach including potential for reduced process performance qualification (PPQ) runs and concurrent process validation. Lexeo is proceeding with validation and commercial manufacturing readiness activities to support the Biologic License Application (BLA) submission for LX2006.
- In March 2026, Lexeo shared updated interim clinical data for LX2006 at the ACC Annual Meeting.
- Phase I/II interim clinical data continue to show sustained or deepening improvements across both cardiac and neurologic measures of FA, including statistically significant improvement in mean mFARS scores for LX2006-treated participants compared to a propensity-matched control cohort from the UNIFAI natural history study.
- LX2006 remains generally well tolerated with no Grade 3+ SAEs to date.
- Anticipated milestones for the remainder of 2026 include:
- FDA feedback on protocol submission expected in Q2 2026
- Initiate SUNRISE-FA 2 pivotal trial in the first half of 2026
LX2020 in PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)
- In January 2026, Lexeo reported positive interim clinical data from the HEROIC PKP2 Phase I/II clinical trial evaluating LX2020. Clinical data from the program were presented at the ACC Annual Meeting in March 2026.
- Cardiac biopsy assessments demonstrated dose dependent increases in PKP2 protein expression, vector copy number, and transgene mRNA.
- In high-dose cohorts, mean arrythmia burden was reduced at the latest visit and the majority of participants reported symptom improvement.
- LX2020 remains generally well tolerated across ten participants dosed with no clinically significant complement activation to date.
- Anticipated milestones for the remainder of 2026 include:
- 12-month data update for all high dose participants in Q4 2026
- Regulatory engagement with the FDA expected in 2026
Corporate Updates
- Strengthened cardiovascular and commercial expertise through key leadership appointments, including the appointment of Narinder Bhalla, MD, as Chief Medical Officer. Dr. Bhalla brings deep experience building and scaling global medical and clinical development organizations and leading successful product launches, most recently at Bristol Myers Squibb and at AstraZeneca. Additional senior leadership appointments further underscore Lexeo’s expanding capabilities in cardiovascular medicine and late-stage clinical development.
- Established research collaboration with Johnson & Johnson to explore targeted cardiac delivery of AAV gene therapy. Collaboration combines Lexeo’s expertise in cardiac genetic medicine with Johnson & Johnson’s expertise in cardiovascular therapeutics and circulatory technologies, including Impella™ heart pumps, to enable the accelerated development of a preclinical cardiac target using novel, localized routes of viral gene therapy administration.
- Executed
$154 million equity financing in October 2025 to further advance development of the company’s cardiac pipeline and to support registrational readiness activities for LX2006.
Fourth Quarter and Full Year 2025 Financial Results
- Cash Position: As of December 31, 2025, cash, cash equivalents, and investments in marketable securities were
$246.6 million , which Lexeo believes will be sufficient to fund operations into 2028. - Research & Development Expenses: Research and Development expenses were
$16.2 million for the three months ended December 31, 2025, compared to$18.4 million for the three months ended December 31, 2024. Research and Development expenses were$63.8 million for the year ended December 31, 2025, compared to$74.1 million for the year ended December 31, 2024. - General & Administrative Expenses: General and Administrative expenses were
$6.9 million for the three months ended December 31, 2025, compared to$9.0 million for the three months ended December 31, 2024. General and Administrative expenses were$45.5 million for the year ended December 31, 2025, compared to$31.7 million for the year ended December 31, 2024. - Net Loss: Net loss was
$20.9 million or$0.27 per share (basic and diluted) for the three months ended December 31, 2025, compared to$25.9 million or$0.78 per share (basic and diluted) for the three months ended December 31, 2024. Net loss was$100.0 million or$1.86 per share (basic and diluted) for the year ended December 31, 2025, compared to$98.3 million or$3.09 per share (basic and diluted) for the year ended December 31, 2024.
About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The Company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 in Friedreich ataxia (FA), LX2020 in plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Lexeo’s expectations and plans regarding its current product candidates and programs and the timing for receipt and announcement of data from its clinical trials, the timing and likelihood of potential regulatory developments and approval, expectations regarding the time period over which Lexeo’s capital resources will be sufficient to fund its anticipated operations and estimates regarding Lexeo’s financial condition. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Lexeo believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements. These forward-looking statements are based upon current information available to the company as well as certain estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Lexeo’s filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond the company’s control and subject to change. Actual results could be materially different from those indicated by such forward-looking statements as a result of many factors, including but not limited to: risks and uncertainties related to global macroeconomic conditions and related volatility; expectations regarding the initiation, progress, and expected results of Lexeo’s preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; delays in submission of regulatory filings or failure to receive regulatory approval; liquidity and capital resources; and other risks and uncertainties identified in Lexeo’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the SEC on November 5, 2025, and subsequent future filings Lexeo may make with the SEC. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Lexeo claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Lexeo expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.
Media Response:
Media@lexeotx.com
Investor Response:
Ashley Kaplowitz
akaplowitz@lexeotx.com
| Lexeo Therapeutics, Inc. Selected Financial Information (in thousands, except share and per share amounts) Statements of Operations | |||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| (unaudited) | (unaudited) | ||||||||||||||
| Operating expenses | |||||||||||||||
| Research and development | $ | 16,210 | $ | 18,366 | $ | 63,797 | $ | 74,091 | |||||||
| General and administrative | 6,906 | 9,016 | 45,460 | 31,675 | |||||||||||
| Total operating expenses | 23,116 | 27,382 | 109,257 | 105,766 | |||||||||||
| Operating loss | (23,116 | ) | (27,382 | ) | (109,257 | ) | (105,766 | ) | |||||||
| Other income and expense | |||||||||||||||
| Gain on long-term investment | - | - | 3,390 | - | |||||||||||
| Other income (expense), net | 9 | - | (18 | ) | (9 | ) | |||||||||
| Interest expense | (20 | ) | (30 | ) | (95 | ) | (137 | ) | |||||||
| Interest income | 2,213 | 1,465 | 6,130 | 7,556 | |||||||||||
| (Amortization of premium) accretion of discount on investments in U.S. Treasury securities, net | (5 | ) | 23 | (111 | ) | 23 | |||||||||
| Total other income and expense | 2,197 | 1,458 | 9,296 | 7,433 | |||||||||||
| Loss from operations before income taxes | (20,919 | ) | (25,924 | ) | (99,961 | ) | (98,333 | ) | |||||||
| Income taxes | - | - | - | - | |||||||||||
| Net loss | $ | (20,919 | ) | $ | (25,924 | ) | $ | (99,961 | ) | $ | (98,333 | ) | |||
| Net loss per common share, basic and diluted | $ | (0.27 | ) | $ | (0.78 | ) | $ | (1.86 | ) | $ | (3.09 | ) | |||
| Weighted average number of shares outstanding used in computation of net loss per common share, basic and diluted | 76,356,996 | 33,076,094 | 53,645,323 | 31,787,491 | |||||||||||
| Balance Sheet Data | ||||||
| December 31, | December 31, | |||||
| 2025 | 2024 | |||||
| Cash, cash equivalents, and investments in U.S. Treasury securities | $ | 246,568 | $ | 128,530 | ||
| Total assets | 268,688 | 146,942 | ||||
| Total liabilities | 22,019 | 30,100 | ||||
| Total stockholders' equity | 246,669 | 116,842 | ||||
FAQ
What did Lexeo (LXEO) report about cash and runway on March 30, 2026?
Has Lexeo (LXEO) received any FDA manufacturing or protocol clearances for LX2006?
When will Lexeo (LXEO) initiate the SUNRISE-FA 2 pivotal trial for LX2006?
What interim clinical results did Lexeo (LXEO) present for LX2006 at ACC 2026?
What clinical evidence supports LX2020 progress for PKP2-ACM reported March 30, 2026?
How did Lexeo (LXEO) fund its 2025 development plans and what was the financing size?
